Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05115513 · ClinicalTrials.gov registry record · Phase 1
Standardized Field Test for Marijuana Impairment II
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05115513 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 41 participants.
The verdict
NCT05115513, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This research responds to NHTSA's request with a proposal to increase our understanding of smoked cannabis' (CNB's) acute effects on driving-relevant cognition and simulated driving performance, the persistence of these deficits over the hours after use, and the influence of prior experience with CNB on these effects. This extension study will aim to further investigate marijuana impaired behavior, using a similar design to our previous NHTSA Examine the Feasibility of a Standardized Field Test for Marijuana Impairment and the prior NIDA Neuroscience of Marijuana-Impaired Driving award, that used similar techniques and measures to quantify marijuana impaired automobile driving. We will be utilizing tasks and assessments that were shown to be strong indicators for cognitive and driving impairment in our NHTSA study.
Interventions
- DRUG Placebo THC
- DRUG Medium THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05115513
The ClinicalTrials.gov registry entry for NCT05115513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo THC is the first listed.
NCT05115513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05115513 about?
NCT05115513 is a clinical study titled "Standardized Field Test for Marijuana Impairment II". This research responds to NHTSA's request with a proposal to increase our understanding of smoked cannabis' (CNB's) acute effects on driving-relevant cognition and simulated driving performance, the persistence of these deficits over the hours after use, and the influence of prior experience with CN...
What is the current status of trial NCT05115513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2022-08-25. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT05115513?
The interventions under investigation include: Placebo THC (DRUG), Medium THC (DRUG).
Who is sponsoring clinical trial NCT05115513?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.